Geoffrey McDonough, CEO: "The third quarter continued to demonstrate solid
underlying growth in product sales and an improvement of the gross margin in
line with our expectations. In September we reported positive top-line results
from our factor IX phase III program with Biogen Idec for the development of a
long-lasting recombinant coagulation factor for hemophilia B. In addition we
were granted priority review by the FDA for our application for Kineret® for the
NOMID indication with an expected approval date in late December 2012. We also
continued to strengthen the Partner Product portfolio through the extension and
expansion of several existing partnerships."
